JPWO2021032961A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021032961A5
JPWO2021032961A5 JP2022509630A JP2022509630A JPWO2021032961A5 JP WO2021032961 A5 JPWO2021032961 A5 JP WO2021032961A5 JP 2022509630 A JP2022509630 A JP 2022509630A JP 2022509630 A JP2022509630 A JP 2022509630A JP WO2021032961 A5 JPWO2021032961 A5 JP WO2021032961A5
Authority
JP
Japan
Prior art keywords
cells
cell population
antibody
fragment
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022509630A
Other languages
English (en)
Japanese (ja)
Other versions
JP7764364B2 (ja
JP2022544964A (ja
JP2022544964A5 (https=
Publication date
Priority claimed from GBGB1911799.3A external-priority patent/GB201911799D0/en
Priority claimed from GBGB2010760.3A external-priority patent/GB202010760D0/en
Priority claimed from GBGB2012172.9A external-priority patent/GB202012172D0/en
Priority claimed from PCT/GB2020/051956 external-priority patent/WO2021032961A1/en
Application filed filed Critical
Publication of JP2022544964A publication Critical patent/JP2022544964A/ja
Publication of JP2022544964A5 publication Critical patent/JP2022544964A5/ja
Publication of JPWO2021032961A5 publication Critical patent/JPWO2021032961A5/ja
Priority to JP2025121129A priority Critical patent/JP2025165980A/ja
Publication of JP7764364B2 publication Critical patent/JP7764364B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022509630A 2019-08-16 2020-08-14 エクスビボγδ Ｔ細胞集団 Active JP7764364B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025121129A JP2025165980A (ja) 2019-08-16 2025-07-18 エクスビボγδ Ｔ細胞集団

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1911799.3A GB201911799D0 (en) 2019-08-16 2019-08-16 Novel Antibodies
GB1911799.3 2019-08-16
GB2010760.3 2020-07-13
GBGB2010760.3A GB202010760D0 (en) 2020-07-13 2020-07-13 Novel antibodies
GB2012172.9 2020-08-05
GBGB2012172.9A GB202012172D0 (en) 2020-08-05 2020-08-05 Gamma delta cell populations
PCT/GB2020/051956 WO2021032961A1 (en) 2019-08-16 2020-08-14 Ex vivo gamma delta t cell populations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025121129A Division JP2025165980A (ja) 2019-08-16 2025-07-18 エクスビボγδ Ｔ細胞集団

Publications (4)

Publication Number Publication Date
JP2022544964A JP2022544964A (ja) 2022-10-24
JPWO2021032961A5 true JPWO2021032961A5 (https=) 2023-08-21
JP2022544964A5 JP2022544964A5 (https=) 2023-08-21
JP7764364B2 JP7764364B2 (ja) 2025-11-05

Family

ID=72148175

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022509630A Active JP7764364B2 (ja) 2019-08-16 2020-08-14 エクスビボγδ Ｔ細胞集団
JP2025121129A Pending JP2025165980A (ja) 2019-08-16 2025-07-18 エクスビボγδ Ｔ細胞集団

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025121129A Pending JP2025165980A (ja) 2019-08-16 2025-07-18 エクスビボγδ Ｔ細胞集団

Country Status (12)

Country Link
US (1) US20220290101A1 (https=)
EP (1) EP4013787A1 (https=)
JP (2) JP7764364B2 (https=)
KR (1) KR20220045980A (https=)
CN (1) CN114599783A (https=)
AU (1) AU2020334287A1 (https=)
BR (1) BR112022001416A2 (https=)
CA (1) CA3148588A1 (https=)
IL (1) IL290538A (https=)
MX (1) MX2022001977A (https=)
PH (1) PH12022550373A1 (https=)
WO (1) WO2021032961A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531787B (zh) 2015-01-27 2022-01-18 拉法医疗有限公司 靶向cd1d的单域抗体
WO2020060406A1 (en) 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
LT4269444T (lt) 2020-08-14 2024-09-25 GammaDelta Therapeutics Limited Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai
GB202013962D0 (en) 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
TW202246338A (zh) * 2021-02-17 2022-12-01 英商適應生物治療有限公司 抗ＴＣＲδ可變1抗體
AU2022222299A1 (en) 2021-02-17 2023-09-07 F-Star Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
JP2024539088A (ja) * 2021-10-20 2024-10-28 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 腫瘍浸潤ガンマ－デルタｔ細胞を拡大するための方法及び材料
CA3238458A1 (en) * 2021-11-18 2023-05-25 Regents Of The University Of Minnesota Large-scale expansion of engineered human gamma delta t cells
WO2024259371A2 (en) * 2023-06-14 2024-12-19 Duke University COMPOSITIONS FOR AND METHODS OF EXPANDING γδ T CELLS
CN121752599A (zh) * 2023-08-31 2026-03-27 南京传奇生物科技有限公司 抗γδTCR抗体及其用途
CN120058919B (zh) * 2025-04-29 2025-07-18 浙江大学杭州国际科创中心 抗裂谷热病毒Gn蛋白的单抗及在病毒检测中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103635573B (zh) 2011-05-19 2016-05-11 分子医学研究所 包含γδT细胞的淋巴细胞系、其组合物及生产方法
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
EP4148124A1 (en) 2015-10-30 2023-03-15 Cancer Research Technology Limited Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
EP3454870A4 (en) 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
US10519236B2 (en) * 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells

Similar Documents

Publication Publication Date Title
JP7379561B2 (ja) キメラ抗原及びｔ細胞受容体、並びに使用方法
US20250188177A1 (en) Cd70 binding molecules and methods of use thereof
Carrega et al. NCR+ ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures
Lozupone et al. Effect of human natural killer and γδ T cells on the growth of human autologous melanoma xenografts in SCID mice
Pitzalis et al. Ectopic lymphoid-like structures in infection, cancer and autoimmunity
CN102977213B (zh) 抗nkg2a 的单克隆抗体
JPWO2021032961A5 (https=)
Zeng et al. Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives
McQueen et al. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?
TWI807077B (zh) 嵌合抗原受體療法t細胞擴增動力學及其用途
Benito-Miguel et al. IL-15 expression on RA synovial fibroblasts promotes B cell survival
US12187792B2 (en) IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
Ferretti et al. Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma
Sadun et al. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models
JP2022517461A (ja) Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法
US20250313855A1 (en) Chimeric antigen receptor t cell therapy
KR20230129485A (ko) T 세포 요법
US20220378829A1 (en) Genetically engineered immune cells targeting cd70 for use in treating solid tumors
JP2022513412A (ja) 癌を治療するための物質及び方法
Winter et al. Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines
JP2022528238A (ja) がん療法で使用するためのセマフォリン－４ｄアンタゴニスト
US20220202859A1 (en) Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
Kim et al. Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
Meng et al. PD-L1 in plasmacytoid dendritic cells promote HBV persistence through disrupting humoral immune response
JP2023532202A (ja) がん免疫療法に対する応答性を決定する方法